Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Rating of "Buy" by Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned an average recommendation of "Buy" from the nine analysts that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $76.29.

Several brokerages have recently commented on AKRO. Citigroup boosted their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. UBS Group increased their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Canaccord Genuity Group lifted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, insider Timothy Rolph sold 31,250 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the completion of the transaction, the insider now owns 170,237 shares in the company, valued at approximately $9,494,117.49. This represents a 15.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 5,000 shares of the business's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $57.03, for a total value of $285,150.00. Following the completion of the sale, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. This trade represents a 12.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 341,309 shares of company stock valued at $15,863,578 and have sold 242,135 shares valued at $12,064,779. Insiders own 7.94% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. Rhumbline Advisers grew its stake in shares of Akero Therapeutics by 4.7% during the 1st quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock worth $4,481,000 after acquiring an additional 5,001 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Akero Therapeutics by 8,057.1% during the first quarter. GAMMA Investing LLC now owns 10,849 shares of the company's stock worth $439,000 after purchasing an additional 10,716 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Akero Therapeutics in the fourth quarter valued at $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Akero Therapeutics by 18.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company's stock valued at $1,988,000 after buying an additional 11,035 shares during the last quarter. Finally, Woodline Partners LP lifted its position in Akero Therapeutics by 29.9% during the 4th quarter. Woodline Partners LP now owns 379,967 shares of the company's stock worth $10,571,000 after buying an additional 87,499 shares in the last quarter.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO traded down $3.75 during midday trading on Friday, reaching $33.62. 307,752 shares of the company traded hands, compared to its average volume of 852,828. The stock's 50-day simple moving average is $45.66 and its 200-day simple moving average is $35.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics has a 12 month low of $17.86 and a 12 month high of $58.40. The firm has a market cap of $2.68 billion, a PE ratio of -9.04 and a beta of -0.18.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, equities analysts anticipate that Akero Therapeutics will post -3.99 earnings per share for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.